The global market for Glucagon Like Peptide-1 (GLP-1) Agonists was estimated to be worth US$ 8816.2 million in 2023 and is forecast to a readjusted size of US$ 21340 million by 2030 with a CAGR of 13.3% during the forecast period 2024-2030

Glucagon Like Peptide-1 (GLP-1) Agonists - Market

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Glucagon Like Peptide-1 (GLP-1) Agonists, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Glucagon Like Peptide-1 (GLP-1) Agonists by region & country, by Type, and by Application.

The Glucagon Like Peptide-1 (GLP-1) Agonists market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon Like Peptide-1 (GLP-1) Agonists.

Market Segmentation

Scope of Glucagon Like Peptide-1 (GLP-1) Agonists - Market Report

Report Metric	Details
Report Name	Glucagon Like Peptide-1 (GLP-1) Agonists - Market
Forecasted market size in 2030	US$ 21340 million
CAGR	13.3%
Forecasted years	2024 - 2030
Segment by Type:	Exenatied Liraglutide Lixisenatide Albiglutide Dulaglutide
Segment by Application	Hospital Pharmacy Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb, Amylin
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Glucagon Like Peptide-1 (GLP-1) Agonists - Market size in 2030?

Ans: The Glucagon Like Peptide-1 (GLP-1) Agonists - Market size in 2030 will be US$ 21340 million.

What is the market share of major companies in Glucagon Like Peptide-1 (GLP-1) Agonists - Market?

Ans: Novo Nordisk is the top one of this industry by 68% market shares.

What is the Glucagon Like Peptide-1 (GLP-1) Agonists - Market production share by region?

Ans: The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Who are the main players in the Glucagon Like Peptide-1 (GLP-1) Agonists - Market report?

Ans: The main players in the Glucagon Like Peptide-1 (GLP-1) Agonists - Market are Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb, Amylin

What are the Application segmentation covered in the Glucagon Like Peptide-1 (GLP-1) Agonists - Market report?

Ans: The Applications covered in the Glucagon Like Peptide-1 (GLP-1) Agonists - Market report are Hospital, Pharmacy, Other

What are the Type segmentation covered in the Glucagon Like Peptide-1 (GLP-1) Agonists - Market report?

Ans: The Types covered in the Glucagon Like Peptide-1 (GLP-1) Agonists - Market report are Exenatied, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide

1 Market Overview

1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction

1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast

1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)

1.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume (2019-2030)

1.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price (2019-2030)

1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends & Drivers

1.3.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends

1.3.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers & Opportunity

1.3.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges

1.3.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Players Revenue Ranking (2023)

2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2019-2024)

2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Players Sales Volume Ranking (2023)

2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company Players (2019-2024)

2.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Company (2019-2024)

2.6 Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Glucagon Like Peptide-1 (GLP-1) Agonists

2.9 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Analysis

2.9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Exenatied

3.1.2 Liraglutide

3.1.3 Lixisenatide

3.1.4 Albiglutide

3.1.5 Dulaglutide

3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type

3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, by Type (2019-2030)

3.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, by Type (%) (2019-2030)

3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type

3.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, by Type (2019-2030)

3.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, by Type (%) (2019-2030)

3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Pharmacy

4.1.3 Other

4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application

4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, by Application (2019-2030)

4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, by Application (%) (2019-2030)

4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application

4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, by Application (2019-2030)

4.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, by Application (%) (2019-2030)

4.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region

5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2019-2024)

5.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2025-2030)

5.1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (%), (2019-2030)

5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region

5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2019-2024)

5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2025-2030)

5.2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (%), (2019-2030)

5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

5.4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

5.5.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

5.6.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

5.7.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

5.8.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value

6.2.1 Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

6.2.2 Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

6.3.2 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

6.4.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

6.5.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

6.5.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

6.6.2 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

6.7.2 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

6.8.2 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019-2030

6.9.2 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

6.9.3 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Novo Nordisk

7.1.1 Novo Nordisk Company Information

7.1.2 Novo Nordisk Introduction and Business Overview

7.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.1.5 Novo Nordisk Recent Development

7.2 AstraZeneca

7.2.1 AstraZeneca Company Information

7.2.2 AstraZeneca Introduction and Business Overview

7.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)

7.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.2.5 AstraZeneca Recent Development

7.3 Eli Lily

7.3.1 Eli Lily Company Information

7.3.2 Eli Lily Introduction and Business Overview

7.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.3.5 Eli Lily Recent Development

7.4 GSK

7.4.1 GSK Company Information

7.4.2 GSK Introduction and Business Overview

7.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)

7.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.4.5 GSK Recent Development

7.5 Sanofi

7.5.1 Sanofi Company Information

7.5.2 Sanofi Introduction and Business Overview

7.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.5.5 Sanofi Recent Development

7.6 Bristol-Myers Squibb

7.6.1 Bristol-Myers Squibb Company Information

7.6.2 Bristol-Myers Squibb Introduction and Business Overview

7.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.6.5 Bristol-Myers Squibb Recent Development

7.7 Amylin

7.7.1 Amylin Company Information

7.7.2 Amylin Introduction and Business Overview

7.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

7.7.5 Amylin Recent Development

8 Industry Chain Analysis

8.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain

8.2 Glucagon Like Peptide-1 (GLP-1) Agonists Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Model

8.5.2 Sales Channel

8.5.3 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends

Table 2. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers & Opportunity

Table 3. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges

Table 4. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints

Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company (2019-2024)

Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Glucagon Like Peptide-1 (GLP-1) Agonists Price by Company (2019-2024) & (USD/Unit)

Table 10. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Glucagon Like Peptide-1 (GLP-1) Agonists

Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2019-2024) & (USD/Unit)

Table 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2025-2030) & (USD/Unit)

Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2019-2024) & (USD/Unit)

Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2025-2030) & (USD/Unit)

Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2019-2024) & (%)

Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2025-2030) & (%)

Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2019-2024) & (%)

Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Region (2025-2030) & (%)

Table 50. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Region (2019-2024) & (USD/Unit)

Table 51. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Region (2025-2030) & (USD/Unit)

Table 52. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume, (2025-2030) & (K Units)

Table 57. Novo Nordisk Company Information

Table 58. Novo Nordisk Introduction and Business Overview

Table 59. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 60. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 61. Novo Nordisk Recent Development

Table 62. AstraZeneca Company Information

Table 63. AstraZeneca Introduction and Business Overview

Table 64. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 65. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 66. AstraZeneca Recent Development

Table 67. Eli Lily Company Information

Table 68. Eli Lily Introduction and Business Overview

Table 69. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 70. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 71. Eli Lily Recent Development

Table 72. GSK Company Information

Table 73. GSK Introduction and Business Overview

Table 74. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 75. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 76. GSK Recent Development

Table 77. Sanofi Company Information

Table 78. Sanofi Introduction and Business Overview

Table 79. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 80. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 81. Sanofi Recent Development

Table 82. Bristol-Myers Squibb Company Information

Table 83. Bristol-Myers Squibb Introduction and Business Overview

Table 84. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 85. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 86. Bristol-Myers Squibb Recent Development

Table 87. Amylin Company Information

Table 88. Amylin Introduction and Business Overview

Table 89. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 90. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Offerings

Table 91. Amylin Recent Development

Table 92. Key Raw Materials Lists

Table 93. Raw Materials Key Suppliers Lists

Table 94. Glucagon Like Peptide-1 (GLP-1) Agonists Downstream Customers

Table 95. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

List of Figures

Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture

Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume (2019-2030) & (K Units)

Figure 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price (2019-2030) & (USD/Unit)

Figure 6. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered

Figure 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2023

Figure 10. Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Exenatied Picture

Figure 12. Liraglutide Picture

Figure 13. Lixisenatide Picture

Figure 14. Albiglutide Picture

Figure 15. Dulaglutide Picture

Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Type, 2023 & 2030

Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Market Share by Type, 2023 & 2030

Figure 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2019-2030) & (USD/Unit)

Figure 21. Product Picture of Hospital

Figure 22. Product Picture of Pharmacy

Figure 23. Product Picture of Other

Figure 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Application, 2023 & 2030

Figure 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Market Share by Application, 2023 & 2030

Figure 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2019-2030) & (USD/Unit)

Figure 29. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)

Figure 30. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

Figure 31. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)

Figure 32. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

Figure 33. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

Figure 35. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)

Figure 36. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

Figure 37. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)

Figure 38. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (%), 2023 VS 2030

Figure 39. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (%), (2019-2030)

Figure 40. Key Countries/Regions Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume (%), (2019-2030)

Figure 41. United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2019-2030) & (US$ Million)

Figure 42. United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

Figure 43. United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2023 VS 2030

Figure 44. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2019-2030) & (US$ Million)

Figure 45. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

Figure 46. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2023 VS 2030

Figure 47. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2019-2030) & (US$ Million)

Figure 48. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

Figure 49. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2023 VS 2030

Figure 50. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2019-2030) & (US$ Million)

Figure 51. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

Figure 52. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2023 VS 2030

Figure 53. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2019-2030) & (US$ Million)

Figure 54. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

Figure 55. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2023 VS 2030

Figure 56. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2019-2030) & (US$ Million)

Figure 57. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

Figure 58. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2023 VS 2030

Figure 59. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value, (2019-2030) & (US$ Million)

Figure 60. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (%), 2023 VS 2030

Figure 61. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (%), 2023 VS 2030

Figure 62. Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain

Figure 63. Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Cost Structure

Figure 64. Channels of Distribution (Direct Sales, and Distribution)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions